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A Single-Subject Evaluation of the Treatment of Morphing Fear 
 
Abstract 
We present a single-subject prospective outcome study of a man with severe morphing fear 
who was not helped by previous interventions, and who received an adapted form of cognitive 
behaviour therapy (CBT) as part of this study. Treatment consisted of a cognitively-focused 
approach tailored to address his fear of morphing and included helping him develop a stronger 
sense of self-stability. We describe the details of the case, the treatment protocol, and the 
therapeutic outcomes as assessed by questionnaires, rating scales and semi-structured interviews 
over 36 weeks. The intervention was effective in eradicating the patient’s morphing fears and 
reducing other symptoms of OCD, anxiety and depression. The presented case illustrates the need to 
appropriately conceptualize, assess and address the specific nature of morphing fear symptoms in 
treatment. 
 
Key words: morphing fear, transformation obsession, mental contamination, obsessive-
compulsive disorder, treatment efficacy 
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Introduction 
The current National Institute for Health and Care Excellence (NICE) guidelines (2005) 
recommend cognitive behavioural therapy (CBT) incorporating exposure and response prevention 
(ERP) for the treatment of Obsessive Compulsive Disorder (OCD) in the UK. Unfortunately, there 
remains considerable scope for improvement in treatment efficacy with various studies showing that 
following the recommended treatment for OCD only up to one-quarter of patients demonstrate 
complete recovery (Abramowitz, Franklin, & Foa, 2002; Boschen, Drummond, & Pillay, 2008; 
Eddy, Dutra, Bradley, & Westen, 2004; Fisher & Wells, 2005). Some evidence suggests that 
treatment outcomes for contamination-related OCD in particular are modest; many contamination-
fearful patients do not achieve symptom relief or commonly relapse following initial successful 
treatment (Coelho & Whittal, 2001, cited in Rachman, 2004; McLean et al., 2001). Given that 
contamination fears account for up to 55% of people with OCD (Calamari et al., 2004; Foa & 
Kozak, 1995; Rachman, 2004; Rachman & Hodgson, 1980; Rasmussen & Eisen, 1992), increasing 
success rates of contamination fear treatment is imperative. 
One potential explanation for the poor outcomes of contamination fears is the failure to 
conceptualize these symptoms adequately. This may in part be due to over-attention paid to contact 
contamination and overlooking contamination fears which arise in the absence of physical contact 
(i.e. mental contamination; Fairbrother & Rachman, 2004; Rachman, 2006; Radomsky & Elliott, 
2009) and those which may present as more obscure symptoms (i.e. morphing fears, cf. Rachman, 
2006; Volz & Heyman, 2007). It has previously been suggested that different OCD symptom 
profiles may require tailored CBT interventions to increase efficacy of treatment (Freeston et al., 
1997; Keeley, Storch, Merlo, & Geffken, 2008; Sookman et al., 2005; Williams, Salkovskis, 
Forrester, & Allsopp, 2002). NICE guideline-recommended treatment for OCD may need 
adaptation for mental contamination and morphing fears in order to specifically target the key 
presenting symptoms of these OCD manifestations. 
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Mental contamination is defined by feelings of dirtiness and urges to wash which arise in the 
absence of direct contact with a noxious substance or following contact with something others 
would not deem contaminating (Rachman, 1994, 2004, 2006). Morphing fear, a type of mental 
contamination (Coughtrey et al., 2013; Rachman, 2006; Zysk, Shafran, Williams & Melli, 2015), 
involves worries that one may become tainted by and acquire unwanted characteristics of others 
through contagion. Patients commonly interpret this fear as becoming contaminated and harmed by 
others’ qualities (Coughtrey et al., 2012; Monzani et al., 2015; Rachman, 2006) thereby bearing 
resemblance to other contamination fears, although overt washing/cleaning compulsions may or 
may not present. Morphing fears commonly present as avoidance of a specific person or group who 
may be deemed inferior or undesirable, with compulsions presenting in overt (e.g. washing, 
checking, reassurance seeking) and covert (e.g. mental cleansing, neutralising) forms. Unlike with 
contact contamination, the source of mental contamination and morphing fears is cognitive; for 
instance, morphing fears can be elicited through looking at, hearing or thinking about an 
undesirable person. Additionally, the resulting feelings of contamination are internal and 
psychological. As such, the site of contamination is not physically accessible, and washing is 
misdirected and often does not bring relief (Rachman, 2006).  
The prominent symptom in morphing fear is an underlying concern about magical 
transformation, a cognitively-based fear grounded in a cause-and-effect distortion that patients 
recognize as irrational. The intrusive recurring nature of the thoughts has led morphing fears to also 
be referred to as “transformation obsessions” (Monzani et al., 2015; Volz & Heyman, 2007) and 
these symptoms have recently been found to load onto the forbidden thoughts dimension of the 
Children's Yale-Brown Obsessive-Compulsive Scale checklist (Scahill et al., 1997) in children 
(Monzani et al., 2015). The cognitive nature of morphing fears is also reflected in patients’ unstable 
sense of self and concurrent low self-esteem (cf. Rachman, 2006). People with OCD hold uncertain 
self-perceptions and are prone to experiencing ego-dystonic intrusions as personally threatening to 
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their sense of self (Bhar & Kyrios, 2007; Ferrier & Brewin, 2005; Guidano & Liotti, 1983; Lipton, 
Brewin, Linke, & Halperin, 2010). Such intrusions may lead some people to fear they may become 
someone undesirable (O'Connor et al., 2005; Wu, Aardema & O’Connor, 2009) which may help 
explain morphing fears. Previous research has also shown links between feared self-beliefs and self-
doubt in OCD (Nikodijevic, Moulding, Anglim, Aardema, & Nedeljkovic, 2015). In addition, self-
esteem—which is thought to be linked with self-uncertainty (Campbell, 1990)—may be affected by 
the exaggerated importance of intrusions about patients’ identity (Ferrier & Brewin, 2005) and 
morality (Shafran, Thordarson, & Rachman, 1996). As such, these cognitions may lead patients to 
engage in compulsions such as checking and neutralising to reduce the doubt and threat and to 
correct any perceived deviation from the actual self (cf. Bhar & Kyrios, 2007; Guidano & Liotti, 
1983).  
Three treatment recommendations for morphing fears have been proposed: exposure and 
response prevention (ERP; Hevia, 2009), standard CBT treatment (Monzani et al., 2015; Volz & 
Heyman, 2007), and theory-driven cognitively-focused CBT (Rachman, 2006; Rachman, 
Coughtrey, Shafran, & Radomsky, 2015). Hevia (2009) describes a retrospective case of a male 
who was successfully treated with a course of ERP. Volz and Heyman (2007) and Monzani et al. 
(2015) suggest the same application of CBT for morphing fear as for other symptoms of OCD; this 
approach was used for children with OCD who were additionally retrospectively found to have had 
morphing fears, and showed comparable success in their general OCD reduction as those with OCD 
not having reported any morphing fears (Monzani et al., 2015). However, given the cognitive nature 
of morphing fears, Rachman (2006; Rachman et al., 2015) argues that morphing fears require a 
cognitively-focused CBT approach similar to that for mental contamination. A cognitive focus 
allows for idiographic treatment to address specific OCD symptom presentation and target 
underlying cognitive processes that contribute to their maintenance (cf. Rachman, 2003; Whittal, 
Robichaud, & Woody, 2010; Wilhelm et al., 2009). Specifically, Rachman proposes techniques 
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aimed to target maladaptive cognitions and key underlying beliefs and working with the patient to 
develop a stronger sense of self-stability could prove useful in alleviating morphing fears. This 
treatment has since been shown to be effective (cf. Coughtrey et al., 2013; Rachman et al., 2015).  
From the morphing fear research to date, Coughtrey et al.’s (2013) study is the only one to have 
utilized a prospective design; the retrospective nature of the research by Hevia (2009), Volz and 
Heyman (2007) and Monzani et al. (2015) does not permit for confidence in their findings. A 
further critical limitation of published work to date rests in that reduction of morphing fears was not 
systematically measured so it is unclear to what extent treatment gains were morphing-fear specific. 
The aim of the current study is to evaluate a theory-driven cognitive behavioral intervention 
specifically focused on morphing fears based on Rachman’s (2006; Rachman et al., 2015) treatment 
recommendations, and with a heavy focus on working to build a robust sense of self. It is 
hypothesized that this specialized treatment would result in clinically significant decreases in 
morphing fears, mental contamination, obsessive-compulsive (OC) symptoms, anxiety, and 
depression. This study uses a single-subject multiple baseline design to test the hypotheses. Single-
subject designs are critical in testing theoretically-derived interventions and establishing evidence-
based practice (Agras & Berkowitz, 1980; Horner et al., 2005; Kazdin, 1982; Salkovskis, 2002), 
and are particularly important where there have been previous treatment failures, when no specific 
treatments exist, and in investigations involving unusual or rare phenomena (Blampied, 1999; 
Kazdin, 1982). Single-subject designs are rigorous methods for evaluating treatment efficacy 
(Horner et al., 2005) and are thought to provide the greatest understanding of treatment effects 
(Barlow, 1981; Shadish, Cook, & Campbell, 2002; Valsiner, 1986). The existence of a new valid 
and reliable measure to assess morphing fears (Morphing Fear Questionnaire; Zysk et al., 2015) 
allows the current research to improve on past treatment studies in order to provide unequivocal 
support for symptom change. The use of this measure also allows for an objective, clear and 
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complete definition of morphing fears, thereby meeting the criteria put forth by Hawkins and Dobes 
(1977). 
Methods 
Design 
An A-B design was used in which symptoms of one patient were assessed over 36 weeks: 
symptoms were monitored at baseline before the intervention was applied and throughout treatment 
until after its completion. This study received NHS (XX/XX/XX) and university ethical approval.  
Participant 
James1 was a male in his twenties who was referred by a mental health practitioner. The 
referral mentioned James’s OCD symptoms (e.g. compulsive washing and checking), symptoms of 
mental contamination (e.g. feelings of dirtiness following conflict), and symptoms which suggested 
possible morphing fears (e.g. worries that he will be weakened as a person). Upon assessment, the 
patient was confirmed to have a primary diagnosis of OCD; have morphing fears which cause 
significant distress and interference; not be actively psychotic or suicidal, and not be receiving any 
concurrent psychological treatment; and was thereby suitable for treatment. James had a 15 year 
history of OCD. Prior treatment included face-to-face and phone sessions of counselling which 
James described as very unhelpful. He had been previously prescribed Fluoxetine for depression 
and anxiety on two occasions. At the time of the assessment and treatment James was not taking 
any psychotropic medications. 
James presented with severe morphing concerns related to a fear of losing his intelligence and 
becoming an immoral person. He feared he could become “infected with unseeable germs” and 
change to be like another person through physical contact or proximity, or through a negative 
                                                          
1
 Personal details have been changed to protect the patient’s identity. Details of the case (referred to as “Joanne”) have been 
presented elsewhere (AUTHORS REMOVED, in press).  
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atmosphere created by a person or group. The feared changes could involve physical (e.g. becoming 
less attractive or disabled), moral (becoming violent, sexist, racist, or “sleazy”), emotional 
(acquiring a negative mood or becoming insecure or pathetic), or intellectual transformations 
(adopting superstitions, shallow opinions, or viewpoints he did not endorse). Additionally, James 
felt that he needed to maximize his potential and every intellectual and social opportunity due to 
intrusions that if he did not understand something he could become diminished as a person. When 
James felt diminished or experienced low mood, stress or embarrassment, he felt he could 
physically change. In particular, he worried he could become shorter in stature—that he could 
literally become a smaller person. James was also concerned about the possibility of reverse 
morphing. He feared he could infect others with his depression and beliefs, and that others could 
take away his positive traits for their own use. 
The patient was preoccupied by these distressing fears a large proportion of the time and 
engaged in avoidance and compulsions which were primarily geared at stopping him from “losing 
himself”. Compulsions involved hand-washing, performing actions in 3s, touching “safe” objects, 
repetition of information, and checking compulsions comprising thinking of three personal facts 
within a set time limit to verify he was still himself. Due to fears of being wrong or taken off-guard 
in a conversation and thereby appearing stupid, James avoided making an argument unless he was 
confident he was correct, and he reported feelings of panic in some social situations. James avoided 
engaging in banal conversation and exposing himself to shallow opinions or situations which fail to 
stimulate him as he believed these could contaminate him by eroding his intelligence or potential 
and making him dull and uninteresting. James’s need to excel in his work was in part driven by this 
fear; he felt his only salvation was to be able to pursue higher career goals and to be in the company 
of other critically-thinking intellectuals. Ironically, one significant impact of James’s morphing 
fears related to him not doing well in his work. This caused him great distress and anxiety, and 
contributed to his feelings of depression and hopelessness. Feelings of depression, in turn, provided 
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support for James’s belief that he could acquire negative mood and self-pity through morphing, and 
thereby contributed to fear maintenance. In a similar manner, James’s disorganisation and lack of 
routine and sleep caused him to look and feel tired which he sometimes took as evidence of change. 
James additionally had perfectionistic standards which helped maintain the disorder. 
An individualized formulation based on a cognitive-behavioral model of OCD (Whittal, 
Woody, McLean, Rachman, & Robichaud, 2010) and theory of mental contamination (Rachman, 
2006) was drawn up between James and his therapist in the first session (see Figure 1). 
[INSERT FIGURE 1 ABOUT HERE] 
Materials 
Morphing Fear Questionnaire (MFQ; Zysk, Shafran, Williams & Melli, submitted). This brief 
13-item self-report measure assesses for the presence and severity of morphing fears on a 5-point 
Likert scale from 0 (not at all) to 4 (very much). Respondents are asked to provide a short 
explanation or specific example for any two questions with which they agree much/very much. This 
unidimentional measure has shown excellent internal consistency in an OCD sample (α = .90), good 
temporal stability (r = .73), and excellent construct validity (e.g. convergence with the OCI-R and 
VOCI-MC, and divergence with BDI-II and BAI). The MFQ has shown evidence of criterion-
related validity in its ability to discriminate between groups reporting OCD, anxiety, depression and 
no OCD. 
Vancouver Obsessional Compulsive Inventory - Mental Contamination Scale (VOCI-MC; 
Rachman, 2006). This 20-item self-report measure assesses presence of mental contamination using 
items such as “I often feel dirty inside my body” rated on a 5-point Likert scale (0–4). The VOCI-
MC has excellent internal consistency (Cronbach’s α = .93−.97), good convergent validity with the 
contamination subscale of the VOCI (cf. Thordarson et al., 2004) and divergent validity with 
symptoms of depression on the BDI-II, and good discriminant validity between those with 
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contamination OCD and other groups (Radomsky, Rachman, Shafran, Coughtrey & Barber, 2014). 
An OCD contamination-fearful sample had a mean score of 30.6, while a non-clinical sample had a 
mean of 8.3 (Radomsky et al., 2014). 
Obsessional Compulsive Inventory - Short Version (OCI-R; Foa et al., 2002). The OCI-R 
assesses for OCD symptoms on 6 subscales using 18 items rated on a 5-point Likert scale from 0 
(not at all distressed/bothered) to 4 (extremely distressed/bothered). This self-report measure is 
reported to have good to excellent internal consistency, temporal stability, and convergent validity 
(e.g. washing subscale: Cronbach’s α = .86; rs = .86; strong correlation with Rachman and 
Hodgson’s 1980 Maudsley Obsessive-Compulsive Inventory washing subscale, rs = .78, 
respectively). The mean for OC and non-clinical samples have been reported to be 28.0 and 18.8 
respectively. 
Beck Anxiety Inventory (BAI; Beck & Steer, 1990). The BAI lists 21 symptoms of anxiety on 
which participants rate their symptom severity using a 4-point scale (from 0: not at all to 3: 
severely). The BAI is widely used in research and clinical practise, and has excellent internal 
consistency (Cronbach’s α = .94) and acceptable test-retest reliability (r = .67; Fydrich, Dowdall, & 
Chambless, 1992). The non-clinical mean for this measure has been reported between to be 6.6 
(Gillis, Haaga, & Ford, 1995) and 13.4 (Creamer, Foran, & Bell, 1995) while the clinical mean has 
been found to be 25 in those with a primary anxiety disorder (Beck, Epstein, Brown, & Steer, 
1988). 
Beck Depression Inventory−II (BDI-II; Beck, Steer & Brown, 1996). The 21-item self-report 
measure assesses the presence and severity of the affective, cognitive, motivational, psychomotor, 
and vegetative components of depression. Items are scored from 0 (absent) to 3 (severe). The BDI-
II has shown excellent internal consistency (Cronbach’s α = .91) and test-retest reliability (r = .93), 
and is one of the most widely used measures for assessing depression in research and clinical 
contexts. The non-clinical mean has been reported to be between 8.4 (Whisman, Perez & Ramel, 
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2000) and 12.6 (Beck et al., 1996), while the clinical mean for those with depression has been 
reported at 21.9 (Beck et al., 1996), 
Anxiety Disorders Interview Schedule (ADIS−IV, Brown, Di Nardo & Barlow, 1994). This is a 
widely used semi−structured diagnostic interview with excellent psychometric properties. It 
assesses current episodes of mental health disorders such as anxiety and depression in accord with 
DSM−IV criteria (APA, 1994). 
Yale−Brown Obsessive Compulsive Scale (Y−BOCS; Goodman et al., 1989a). This semi-
structured interview employs both a checklist to assess the nature of the disorder and a 10-item 0-4 
Likert scale to measure the severity of obsessions and compulsions. It has established excellent 
reliability and validity (Goodman et al., 1989a, 1989b). The Y-BOCS is sensitive to treatment 
effects and is considered the “gold-standard” assessment measure in treatment outcome research 
(Frost, Steketee, Krause, & Trepanier, 1995; Taylor, 1995). There has been no established non-
clinical normative data for the Y-BOCS (Fisher & Wells, 2005); however, it is generally accepted 
that a total score of ≤12 is indicative of a functional, non-clinical state (cf. Fisher & Wells, 2005; 
e.g. McLean et al., 2001). A total score of ≥16 signifies clinically symptomatic levels and is 
typically used as entry criteria for treatment trials (Tolin, Abramowitz, & Diefenbach, 2005). 
Standardized Interview Schedule—Contamination (Shortened Version) (Rachman, 2006). This 
interview assesses for the presence and features of contact and mental contamination, with two 
questions specifically assessing for the presence of morphing fears. 
Visual Analogue Scale (VAS): A series of 10cm VASs were used to measure self-report current 
ratings of internal dirtiness, general dirtiness, washing/neutralising urges, and anxiety. Each scale 
was anchored with the labels Not at all to Extremely. The VASs were used as session-by-session 
measures given that such measurement has been shown to improve outcome (cf. Lambert, 2009; 
Lambert, et al., 2001). Additionally, VASs are reliable and valid (Reips & Funke, 2008), help rule 
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out threats to internal validity related to assessment (cf. Kazdin, 1982), and are recognized to be 
sensitive to clinical change (cf. McCormack, Horne, & Sheather, 1988). 
Procedure: 
James was seen within 15 days of his referral for an assessment with a clinical psychologist 
([INITIALS REMOVED], the second author) as part of a research study. He completed a battery of 
questionnaires (i.e. the MFQ, VOCI-MC, OCI-R, BAI & BDI-II) the day before the initial 
assessment which he was asked to bring to the appointment. James provided written informed 
consent to taking part in the research, being audiotaped in treatment and assessment sessions, and 
for his case to be presented in in any publications. 
Clinical Assessment: An initial 90 minute clinical assessment was conducted with the therapist 
following the adaptations put forth by Rachman (2006; Rachman et al., 2015) to get a thorough 
understanding of the main presenting problem, its history and onset. This included: using tools 
specific to assessment of mental contamination (e.g. VOCI-MC) and morphing fears (MFQ); 
determining the source(s) of feelings of contamination and morphing triggers; determining the 
feared/believed mechanism of morphing and assessing the personal vulnerability to contamination 
and morphing; and understanding specific maintaining mechanisms of the fear and how the patient 
makes sense of the problem and its maintenance. 
Independent research assessments: Regular research assessments were held 8–11 weeks apart 
by an experienced independent assessor ([INITIALS REMOVED], the first author) who was blind 
to when the treatment commenced. The initial research assessment (Week 0) was conducted one 
week after the clinical assessment and comprised the ADIS-IV, Y-BOCS, Standardized Interview 
Schedule for Contamination, a brief interview based on high scores on the initial MFQ, and the 
VAS. All subsequent research assessments comprised only the ADIS-IV, Y-BOCS and VAS. The 
patient was asked to complete the battery of questionnaires online within one day of each of the 4 
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subsequent research assessments to collect self-reported symptoms. A delay was planned before the 
start of treatment to assess for symptom improvement without intervention. The second baseline 
research assessment was completed at Week 9, just prior to the commencement of treatment which 
(unbeknown to the assessor) was scheduled to begin the same day. The final assessment was held 
2.5 weeks after the end the final session. 
Session-by-session assessments: The patient also completed the VAS at the start of each 
treatment session to collect regular and frequent assessment over time in order to monitor treatment 
progress (cf. Egan & Hine, 2008; Kazdin, 1982).  
Treatment: Fifteen hour-long sessions were delivered over the course of 22 weeks, with two 
sessions being delivered in the first week (cf. Agras, Walsh, Fairburn, Wilson, & Kraemer, 2000; 
Riley, Lee, Cooper, Fairburn, & Shafran, 2007). The main morphing-fear targeted approach 
occurred in the first 12 sessions, with the final 3 sessions focusing primarily around residual 
symptoms of low mood. The therapist delivering the treatment is experienced in treating mental 
contamination and morphing fears. The detailed background for the choice of this approach is 
provided in [AUTHORS REMOVED] (submitted). The treatment was based on modified Cognitive 
Behavior Therapy for mental contamination (Coughtrey et al., 2013) and focused on addressing 
morphing fears and other presenting problems (mental contamination, depression and 
perfectionism). The following elements were added to target James’s morphing fears (cf. Rachman, 
2006; Rachman et al., 2015):  
 Psychoeducation about mental contamination, morphing fears, stability of characteristics and 
possibility of transference of qualities 
 Addressing cognitive biases, testing beliefs and challenging assumptions that maintained 
symptoms, such as through behavioral experiments assessing the feasibility of change (e.g. 
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using photographs and height measurements to test James’s belief that mood can alter 
physical features) 
 Cognitive restructuring through evaluating negative automatic thoughts and beliefs (e.g. “I am 
losing my potential”) such as in keeping thought records; and operationalising “maximum 
potential” 
 Differentiating between feelings and facts and accurately labelling mood states (e.g. 
distinguishing between feelings of contamination and negative emotions, for instance 
labelling a particular emotional state as “stressed” rather than “diminished”) 
 Cognitive-behavioral approaches to strengthen and broaden sense of self-identity and address 
self-esteem issues (e.g. listing his stable characteristics, devising a pie chart of the multi-
faceted nature of his personality [based on Fairburn, 1995]). 
 
Non-specific interventions included: psychoeducation on healthy lifestyle and regular eating, 
sleeping patterns and routines; organisational aids to manage professional workload; surveys to 
assess what others deem important in maximising their success (e.g. balanced lifestyle versus 
thoroughness); work on perfectionism such as use of continuum techniques (Beck, 1995) and 
helping James exercise moderation in his work and decrease avoidance and procrastination 
(Shafran, Egan, & Wade, 2010); relaxing strict rules; tackling self-criticism and low mood; use of 
problem solving and stress-reduction techniques; and encouraging confiding in others. 
Homework in the form of thought records, surveys and behavioral experiments aimed to 
address morphing fears was assigned between sessions. The treatment terminated with the therapist 
and patient devising a relapse prevention plan reviewing what was done in treatment, what the 
patient found to be useful, and how to spot the early signs of a relapse. To summarize treatment 
gains in his morphing symptoms, James was asked to think about how his identity has solidified and 
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become more robust, and how this has contributed to a decrease in his perceived vulnerability to 
morphing, and consequently a reduction of his morphing fears.  
Results 
Table 1 presents the outcome of each of the 5 research assessments. James did not complete the 
online measures at Week 20 so data is missing for this time point on the VOCI-MC, OCI-R, BAI, 
and BDI-II (he completed the MFQ by email). 
[INSERT TABLE 1 ABOUT HERE] 
Experimental Criterion 
The magnitude and rate of the change of symptoms across different phases were visually 
inspected in accordance with recommendations for addressing the experimental criterion in single-
subject research (cf. Kazdin, 1982; Parsonson & Baer, 1986). Changes in the mean and trend were 
most relevant to the research assessment data, whereas changes in mean, trend and latency of the 
change were most relevant to the session-by-session assessments, and these were accordingly 
examined. Figures 2‒4 present James’s symptoms over time on the MFQ, Y-BOCS, VOCI-MC, 
OCI-R, BAI, and BDI-II as assessed at each research assessment.  
[INSERT FIGURES 2, 3 AND 4 ABOUT HERE] 
The severity of morphing fears, mental contamination, OC symptoms assessed by the Y-BOCS, 
and depression was stable over the two baseline assessments in contrast to the decline seen during 
treatment. On all measures there was an evident downward trend between phases and a change in 
mean that were especially pronounced on the MFQ and OCI-R. Symptom stability or a further 
decrease on the measures could be seen at follow-up. The only exception was mental contamination 
which showed an increase between weeks 28 and 36.  
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Figure 5 displays the VAS measures as collected at baseline (bl-1 & bl2-S1), at the start of each 
treatment session (sessions “S” 2‒15), and at a 2.5 week follow-up (FU). 
[INSERT FIGURE 5 ABOUT HERE] 
A change in mean is evident between the baseline and treatment phases, and this is maintained 
at follow-up. All reported symptoms indicate a clear downward trend over the course of treatment. 
The graph also shows a sharp decline between Sessions 5 and 7, and a decrease in variability by the 
final few sessions and follow-up. 
To supplement the visual analysis (cf. Manolov, Losada, Chacón-Moscoso & Sanduvete-
Chaves, 2016) and measure data non-overlap between two phases accounting for level and trend, 
the Tau-U statistic was used (cf. Parker, Vannest, Davis & Sauber, 2011; Vannest, Parker & Gonen, 
2011) This analysis was carried out for the combined 5 research assessment measures relevant to 
OCD symptomatology (MFQ, VOCI-MC, Y-BOCS, OCI-R and BAI), and for the combined VAS 
(internal and general dirtiness, urge to wash, and anxiety). The omnibus Tau-U effect size as 
assessed by the 5 measures was −0.96 signifying a large intervention effect (Parker & Vannest, 
2009), and this non-overlap in confidence intervals between the baseline and treatment phase was 
found to be significant, z = −3.48, p < .001, 90% CI [−1.420, −0.509]. The Tau-U effect size as 
assessed by the VASs was −0.49 signifying a small intervention effect. The difference between the 
two phases was also significant, z = −2.20, p = .028, 90% CI [−0.860, −0.124]. The weighted 
averages of the research assessments and the VAS measurements both met the recommended 
minimum effect size for practical significance (RMPE) for social sciences (i.e. 0.2; Ferguson, 
2009). 
Therapeutic Criterion 
The data were additionally analysed to assess the impact (i.e. clinical significance) of the 
treatment by determining if the patient’s scores after treatment are closer to the mean of the 
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functional than the dysfunctional population (cf. Jacobson & Truax, 1991; definition c). Table 2 
reports clinical significance was achieved on all but one measure. 
[INSERT TABLE 2 ABOUT HERE] 
Discussion 
The results provide preliminary evidence for the efficacy of a cognitively-focused intervention 
for morphing fear which concentrates on solidifying the patient’s sense of self. Prior to treatment, 
James’s fear caused him anxiety and was disruptive to his professional and social life. In the final 
post-treatment assessment James reported no morphing fear; he was no longer concerned about 
acquiring negative characteristics of others, being diminished and losing his intelligence, and his 
score on the MFQ was indistinguishable from a population without morphing fears. James 
developed a more robust sense of self and shed his belief that his response to negative events could 
cause physical changes in himself.  
The treatment protocol was based around the theory that morphing fear is maintained by a low 
sense of self-stability and low self-esteem (cf. Rachman, 2006; Rachman et al., 2015). James’s 
formulation revealed fragile self-concept, poor self-esteem, and doubts about his personal 
characteristics were maintaining factors of his symptoms. Additional maintaining factors in James’s 
case included perfectionism (e.g., in his strive to be intelligent and his fear that his intelligence 
could be eroded through morphing), depression (e.g., he considered low mood as evidence of 
morphing), and disorganisation (e.g., lack of regular routine causing physical signs of tiredness 
which were mistaken as evidence for becoming diminished). Uncertainty about the self and low 
self-esteem have been found to be closely associated with OCD symptoms (cf. Campbell, 1990), 
and low levels of self-esteem, high anxiety and high depression have been linked with feelings of 
instability about one’s character (e.g. Campbell & Lavallee, 1993; Donahue, Robins, Roberts, & 
John, 1993). Ambivalent feelings about the self have also been used to explain why those with OCD 
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have perfectionism, in that they strive towards high standards of personal characteristics and 
conduct (Bhar & Kyrios, 2007). Perfectionism and compulsions have been noted as defensive 
strategies aimed to protect one’s desirable self-image in people with OCD (Guidano & Liotti, 
1983). Each of these maintenance factors was addressed in therapy. Providing alternative appraisals 
of the threat (e.g. that intelligence is important to him and he worries about the threat of its loss) 
appeared to play a significant role in James’s treatment and provided confidence that cognitively-
heavy CBT incorporating work on the sense of self was appropriate and effective for morphing fear 
reduction.  
The treatment also resulted in clinically significant decreases in the patient’s OC symptoms, 
anxiety and depression levels. After treatment James no longer met diagnostic criteria for social 
phobia, and other symptoms of anxiety had decreased. This is noteworthy in light of the fact that 
although some anxiety-reducing techniques were introduced (e.g. relaxation), anxiety was not a 
focus of treatment. Depression symptoms, which were targeted, also decreased between baseline 
and post-treatment. In the final post-treatment assessment James continued to report mild OCD; 
however, residual OCD symptoms were limited to adhering to certain rules and sequences and some 
internal counting compulsions which James explained to be doing out of habit and which only 
caused him mild distress and interference. James’s obsessional routines had decreased significantly, 
and his contamination fears had also diminished. The intervention also appeared to be helpful in 
alleviating James’s symptoms of mental contamination. However, these therapy gains were not 
stable, and an increase in mental contamination (although not near the initial level) was seen at the 
follow-up assessment. It is unknown why his mental contamination fears showed a partial return, 
particularly in light of the stability of other treatment gains. 
Session by session measures showed that the majority change in morphing fear symptoms 
occurred in the first six sessions of therapy. Accordingly, in the fifth treatment session James 
expressed that he noticed a decline in his compulsive routines. By the ninth session he reported 
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feeling less diminished and less susceptible to morphing, and this change was reflected on the MFQ 
in the research assessment held the following week. Overall, the data indicate the largest treatment 
gains were made by the tenth session. This has implications for clinical practise in that a brief 10-
session intervention may be sufficient for less complex symptoms, such as morphing fears without 
co-morbid depression. In the case of James, complicating factors in treatment included severe 
depression, maladaptive perfectionism, disorganisation, and poor homework compliance. 
A key strength of this research rests in the fact that this study is the first to systematically use a 
valid and reliable measure in the assessment of morphing fears over the course of the intervention. 
Previously reported intervention studies did not use a specific measure of morphing fears and 
operationalized treatment gains through general OCD reduction. This did not allow for confident 
conclusion about treatment efficacy for these fears specifically. Any future intervention studies 
would benefit from using the MFQ to quantify and compare morphing fear symptom change. 
Another strength lay in the use of continuous assessments to help rule out threats to internal 
validity (Engel & Schutt, 2009; Kazdin, 1982). Retaining internal validity was also aided by using 
an independent assessor who was blind to when the treatment began. This may have helped reduce 
observer expectancy effect and placed fewer demands on the patient to report treatment gains.  
Treatment effects were detected in various ways, accumulating evidence for the causal role of 
the intervention. For one, visual inspection of the data—a stringent and reliable method in 
identifying treatment effects—consistently indicated a systematic intervention effect; on numerous 
measures symptoms were at the opposite extremes of the assessment range before and after therapy 
signifying unparalleled stability in the data (cf. Kazdin, 1982). A high rate of symptom decline on 
most measures, alongside decreased variability on the VAS assessment towards the end of treatment 
was also indicative of the effectiveness of treatment (cf. Kazdin, 1982). 
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A limitation of this study is that baseline measures were only collected at two points in time (as 
opposed to the minimum recommendation of three for an experimental design, cf. Kratochwill et 
al., 2010; Morgan & Morgan, 2009) making this design quasi-experimental. A second limitation is 
that symptom reduction seen over the treatment phase did not provide unequivocal evidence for 
treatment efficacy using this single-subject design; fluctuations of symptoms over time, 
spontaneous recovery, and/or maturation may add to or account for symptom decline (cf. Kazdin, 
1982). However, due to the longstanding history of the fear in the particular case described here it is 
thought to be unlikely that the strongly held beliefs would have showed such marked improvement 
without intervention, and a more parsimonious explanation is that the intervention accounted for the 
changes. What can be concluded with less confidence is whether treatment gains resulted from 
morphing-fear-specific elements or non-specific aspects of treatment (such as CBT generally or the 
focus on depressive symptoms). 
Future Direction: Single-subject research relies on replication and it has been recommended 
that 3‒6 successful systematic replications should be carried out to allow for reliable causal 
inferences to be made (Barlow & Hersen, 1973; Gallo, Comer & Barlow, 2013). Use of more 
complex designs such as a multiple baseline design to target anxiety, depression and morphing fears 
in different phases of the intervention programme would strengthen the validity of subsequent 
research. A longer follow-up period would help determine the stability of treatment gains over time. 
Future research may benefit from using self-esteem and self-stability measures to examine the 
association between the constructs and determine the relevance of therapeutic work on self-esteem 
and self-stability in alleviating morphing fear. 
Conclusion 
This study has shown treatment success following a theoretically grounded cognitively-focused 
CBT intervention for morphing fears in an OCD patient who had not been helped by previous 
treatments. Independent assessments and self-report session-by-session measures indicated that this 
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specifically-tailored CBT was effective in reducing morphing fears and other symptoms including 
anxiety and depression. The unique symptoms presented in the described case illustrate the need to 
appropriately conceptualize and address the specific nature of morphing fear symptoms in 
treatment. The positive treatment gains exhibited by the patient are encouraging and can help pave 
the way for a refinement of specific CBT interventions for particular concerns. If future replications 
support the results of this study, the described CBT variant can be considered an effective treatment 
for morphing fears.  
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Table 1 Outcomes of the research assessments collected at each of the 5 time points 
 
Week 
# 
Intervention 
Stage 
ADIS-IV 
Diagnoses 
Y-
BOCS 
MFQ 
VOCI-
MC 
OCI
-R 
BAI 
BDI-
II 
0 Baseline 1 
OCD, depression, 
mild social phobia, 
mild GAD 
31 29 59 52 24 42 
 9 Baseline 2 
OCD, depression, 
mild social phobia, 
GAD 
27 28 56 37 12 43 
20 
Post session 
10 
OCD, depression, 
mild social phobia, 
GAD 
27 10 N/A N/A N/A N/A 
28 
Post session 
13 
Mild OCD, mild 
social phobia, mild 
GAD 
20 3 13 12 4 18 
36 Follow-Up 
Mild OCD, mild 
GAD 
14 1 37 15 4 2 
 
 
Table (blinded)
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Table 2   Clinical significance of changes in measures over baseline (mean scores of Weeks 0 and 9) and post-
treatment (Week 36) phases 
Assessment 
Measure 
Baseline 
Mean 
Post-Treatment 
Score 
Non-clinical 
Mean 
Clinical 
Mean 
Clinical Significance 
Achieved 
MFQ 28.5 1 1.8 7.6 Yes 
VOCI-MC 57.5 37 8.3 30.6 No  
OCI-R 44.5 15 18.8 28.0 Yes  
BAI 18.0 4 6.6–13.4 24.6 Yes 
BDI-II 42.5 2 8.4–12.6 21.9 Yes 
Y-BOCS 29.0 14 <13 >16 Yes 
 
 
 
Table (blinded)
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Figure 1  Clinical formulation for James’s morphing fears depicting triggers, symptoms, appraisals, and specific 
mechanisms thought to be maintaining the patient’s disorder 
 
 
 
 
  
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Trigger: Conflict, intrusive thought, 
problem concentrating, proximity to 
person deemed unintelligent 
 
Appraisal: ͞I aŵ griŵy͟; ͞I aŵ 
diŵiŶished as a persoŶ͟; ͞I aŵ 
shorter͟; ͞I have lost poteŶtial͟; ͞My 
iŶtellect has eroded͟ 
 
Intrusive Thought: ͞Have I ŵissed 
aŶythiŶg?͟; "I ŵight appear stupid"; 
"I might say something incorrect";   "I 
could become like that" 
 
 
Belief: “My thoughts 
are important͟ 
Neutralisations & 
Compulsions: washing; 
walking to maximise 
potential; reciting 
information; excessive 
grooming; routines & 
rituals (e.g. in 3s) 
 
Avoidance: 
situations where 
could feel 
diminished; people 
would not want to 
become like 
 
Emotion:     
low mood; 
guilt, anxiety, 
self-criticism; 
self-blame 
Figure (blinded)
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Figure 2 Symptoms of morphing fears at each research assessment 
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Figure 3 Symptoms of OCD (Y-BOCS) at each research assessment  
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Figure 4 Symptoms of OCD (OCI-R), anxiety and depression at each research assessment 
 
 
 
0 
10 
20 
30 
40 
50 
60 
70 
Week 0: 
Baseline 1 
Week 9: 
Baseline 2 
Week 28: 
Post Session 13 
Week 36: 
Follow-Up 
Q
u
e
st
io
n
n
a
ir
e
 S
co
re
 
VOCI-MC OCI-R BAI BDI-II 
Figure (blinded)
Running Head: TREATMENT OF MORPHING FEAR 1 
 
 
 
Figure 5   Symptoms reported on the VAS at baseline, in each treatment session, and at follow-up 
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